Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Nuvalent Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $19.47 (market cap $8.95B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Norwegian Cruise Line Holdings Ltd and Nuvalent Inc are close in size by market cap, and Nuvalent Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NCLH | NUVL | |
|---|---|---|
Market Cap | $8.95B | $9.81B |
Sector | Consumer Cyclical | Technology |
52-Week High | $26.94 | $123.96 |
52-Week Low | $14.79 | $72.16 |
Enterprise Value | $23.92B | $8.52B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
